Immunic/Nela DornerA late-week surprise from Munich-based Immunic, Inc. (listed on Nasdaq as IMUX): the company has launched a follow-on private placement of up to US$400 million and expects to close the financing later this month. At the same time, the biotech is pressing ahead with its transformation in preparation for the potential commercialisation of its lead asset. Current CEO Daniel Vitt will step back once a successor with proven market-launch expertise has been appointed.
Tag Archive for: autoimmunity
ForbionBritish company Sitala Bio Ltd, founded in 2021 by NLRP3 inflammasome expert Matt Cooper, is paying US$670m and giving up to 10% of its shares to Chinese company Shanghai Fosun Pharmaceutical Group Co. Ltd. in exchange for the development and marketing rights to the low-molecular-weight inflammation blocker FXS6837.
Calypso Biotech BV has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up to US$175.
Analysts describe as sporting the €7.1bn for Roche AG’s acquisition of Roivant subsidiary Telavant Holdings.
Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.
Italian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice.